Aquestive Therapeutics (AQST) Competitors $5.38 -0.04 (-0.65%) As of 12:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AQST vs. ADPT, MESO, DYN, HRMY, IMCR, APGE, SRPT, AUPH, CDTX, and VCELShould you be buying Aquestive Therapeutics stock or one of its competitors? The main competitors of Aquestive Therapeutics include Adaptive Biotechnologies (ADPT), Mesoblast (MESO), Dyne Therapeutics (DYN), Harmony Biosciences (HRMY), Immunocore (IMCR), Apogee Therapeutics (APGE), Sarepta Therapeutics (SRPT), Aurinia Pharmaceuticals (AUPH), Cidara Therapeutics (CDTX), and Vericel (VCEL). These companies are all part of the "pharmaceutical products" industry. Aquestive Therapeutics vs. Its Competitors Adaptive Biotechnologies Mesoblast Dyne Therapeutics Harmony Biosciences Immunocore Apogee Therapeutics Sarepta Therapeutics Aurinia Pharmaceuticals Cidara Therapeutics Vericel Aquestive Therapeutics (NASDAQ:AQST) and Adaptive Biotechnologies (NASDAQ:ADPT) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation. Do institutionals & insiders hold more shares of AQST or ADPT? 32.5% of Aquestive Therapeutics shares are owned by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 8.4% of Aquestive Therapeutics shares are owned by insiders. Comparatively, 6.4% of Adaptive Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is AQST or ADPT more profitable? Adaptive Biotechnologies has a net margin of -59.07% compared to Aquestive Therapeutics' net margin of -147.38%. Aquestive Therapeutics' return on equity of 0.00% beat Adaptive Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Aquestive Therapeutics-147.38% N/A -63.87% Adaptive Biotechnologies -59.07%-60.93%-23.03% Which has better valuation and earnings, AQST or ADPT? Aquestive Therapeutics has higher earnings, but lower revenue than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Aquestive Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAquestive Therapeutics$44.13M12.17-$44.14M-$0.70-7.69Adaptive Biotechnologies$205.22M9.83-$159.49M-$0.82-16.15 Does the media refer more to AQST or ADPT? In the previous week, Aquestive Therapeutics had 7 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 12 mentions for Aquestive Therapeutics and 5 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.26 beat Aquestive Therapeutics' score of 0.77 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aquestive Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adaptive Biotechnologies 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, AQST or ADPT? Aquestive Therapeutics has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500. Do analysts prefer AQST or ADPT? Aquestive Therapeutics presently has a consensus target price of $10.29, suggesting a potential upside of 91.01%. Adaptive Biotechnologies has a consensus target price of $12.38, suggesting a potential downside of 6.57%. Given Aquestive Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Aquestive Therapeutics is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aquestive Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88 SummaryAquestive Therapeutics beats Adaptive Biotechnologies on 10 of the 16 factors compared between the two stocks. Get Aquestive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AQST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AQST vs. The Competition Export to ExcelMetricAquestive TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$539.01M$2.51B$5.65B$10.32BDividend YieldN/A56.32%5.68%4.61%P/E Ratio-7.7223.2775.6626.31Price / Sales12.17570.93521.00169.30Price / CashN/A174.1537.5661.52Price / Book-8.165.1712.996.34Net Income-$44.14M$32.95M$3.29B$270.94M7 Day Performance9.01%0.77%-0.03%0.29%1 Month Performance39.51%5.77%4.13%6.89%1 Year Performance10.80%1.81%69.08%29.31% Aquestive Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AQSTAquestive Therapeutics2.0447 of 5 stars$5.39-0.6%$10.29+91.0%+7.5%$539.01M$44.13M-7.72160ADPTAdaptive Biotechnologies3.4122 of 5 stars$13.08+3.7%$12.38-5.4%+207.4%$1.92B$178.96M-15.95790Positive NewsMESOMesoblast2.1546 of 5 stars$15.46+4.3%$18.00+16.4%+123.7%$1.90B$17.20M0.0080DYNDyne Therapeutics3.1825 of 5 stars$12.86-2.2%$34.07+164.9%-60.6%$1.87BN/A-3.33100HRMYHarmony Biosciences4.7041 of 5 stars$32.50+0.3%$51.00+56.9%-29.2%$1.86B$714.73M10.48200Trending NewsAnalyst ForecastIMCRImmunocore2.2366 of 5 stars$34.42-2.3%$56.89+65.3%+14.0%$1.78B$310.20M-86.05320APGEApogee Therapeutics3.0954 of 5 stars$36.86-0.1%$97.29+163.9%-35.9%$1.70BN/A-8.9291News CoveragePositive NewsAnalyst ForecastSRPTSarepta Therapeutics4.3515 of 5 stars$17.47+0.5%$39.32+125.1%-85.4%$1.70B$1.90B-20.081,372Analyst UpgradeAUPHAurinia Pharmaceuticals2.8471 of 5 stars$12.81+0.5%$12.00-6.3%+83.5%$1.68B$235.13M29.79300Positive NewsCDTXCidara Therapeutics4.1587 of 5 stars$66.91+2.0%$64.14-4.1%+722.5%$1.66B$1.27M-6.0190Trending NewsAnalyst ForecastHigh Trading VolumeVCELVericel2.887 of 5 stars$31.42-2.4%$60.40+92.2%-32.4%$1.62B$237.22M261.86300 Related Companies and Tools Related Companies ADPT Alternatives MESO Alternatives DYN Alternatives HRMY Alternatives IMCR Alternatives APGE Alternatives SRPT Alternatives AUPH Alternatives CDTX Alternatives VCEL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AQST) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquestive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aquestive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
